Corvus Pharma Says Data From Atopic Dermatitis Study Shows Favorable Safety Profile; Shares Fall Pre-Bell

In This Article:

Corvus Pharmaceuticals (CRVS) said Wednesday that interim results from a phase 1 trial of its experi

Upgrade to read this MT Newswires article and get so much more.
A Silver or Gold subscription plan is required to access premium news articles.